NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.

XiaoXia WeiJing ZhuangNa LiBin ZhengHong SunJiaQin CaiXuhui HuangGuifeng ZhangJie Zhuang

Published in: International journal of hematology (2021)

NUDT15 genetic testing prior to the initial administration of 6-MP in pediatric ALL patients in China is less expensive than standard dosing without genetic testing.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
young adults
prognostic factors
patient reported outcomes
patient reported